medigraphic.com
ISSN 0301-696X (Print)
Órgano de difusión del Servicio de Sanidad Militar y del Colegio Nacional de Médicos Militares

2017, Number 2

<< Back Next >>

Rev Sanid Milit Mex 2017; 71 (2)

Fructose: Primordial and target causal agent in obesity, metabolic syndrome and diabetes

Castañeda-Morales M

Language: Spanish
References: 10
Page: 93-98
PDF size: 299.62 Kb.


ABSTRACT

Child and adult overweight and obesity have been increasing relentlessly worldwide; consequently, T2DM in adults and even in children. Lack of significant novel interventions to improve the problem prospects is alarming. Data from bench and clinical investigation have identified fructose as an actionable and promising target.


REFERENCES

  1. Lobstein, T. y Jackson-Leach R. Planning for the worst: estimates of obesity and comorbidities in school-age children in 2025. Pediatr. Obes. 2016;11:321-325.

  2. Kim, M-S., Krauczyk, SA., Doridot, L., Fowler, AJ., Wang, JX., Trauger, SA. y cols. ChREBP regulates fructose-induced glucose production independently of insulin signaling. J. Clin. Invest. 2016;126:4372-4386.

  3. Malik, VS. y Hu, FB. Sweeteners and risk of obesity and type 2 diabetes: The role of sugar-sweetened beverages. Curr. Diab. Rep. 2012;12:195-203.

  4. Basu, S., Yoffe, P., Hills, N. y Lustig, RH. The relationship of sugar to population-level diabetes prevalence: An econometric analysis of repeated cross-sectional data. PLoS One 2013;8:e57873.

  5. Lustig, RH., Mulligan, K., Noworolsky, SM., Tai, VW., Wen, MJ., Erkin-Cakmak, A. y cols. Isocaloric fructose restriction and metabolic improvement in children with obesity and metabolic syndrome. Obesity (Silver Spring) 2016;2:453-460.

  6. Ludwig DS. Lowering the bar on the low-fat diet. JAMA 2016;316:2087-2088.

  7. Arantxa Cochero, M., Rivera Dommarco J., Popkin, B. M. y Ng, S. W. Health Aff. 2017 March, doi: 10.1377/hlthaff. 2016.1231.

  8. Alegre-Díaz J, Herrington W, López-Cervantes M, Gnatiuc L, Ramirez R, Hill M, et al. Diabetes and cause-specific mortality in Mexico City. N Engl J Med 2016;17:1961-1971.

  9. Gall J, Frisdal E, Bittar R, Le Goff W, Bruckert E, Lesnik P, y cols. Association of cholesterol efflux capacity with clinical features of metabolic syndrome: Relevance to atherosclerosis. JAHA 2016;5:e004808.

  10. Kassar, O., Pereira Morais, M., Xu, S., Adam EL, Chamberlain, R.C., Jenkis, B. y cols. Macrophage Migration Inhibitory Factor is subjected to glucose modification and oxidation in Alzheimer Disease. Sci. Rep. 2017;23;7:42874. doi: 10. 1038/srep42874




2020     |     www.medigraphic.com